FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...
Vous n'êtes pas connecté
Drugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss. These drugs, called glucagon-like peptide-1 (GLP-1) receptor agonists, are now being investigated for their ability to help other patients, including those with liver disease. For example, GLP-1 agonists are being studied for their use in […]
FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...
FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive...
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive...
FRIDAY, Oct. 25, 2024 -- For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic...
MONDAY, Oct. 28, 2024 -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium...
FRIDAY, Oct. 25, 2024 -- As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim...
TUESDAY, Oct. 29, 2024 -- Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)...
Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and...
MONDAY, Oct. 28, 2024 -- The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows. Patients taking semaglutide...